Abstract
With 49 members identified thus far, the superfamily of nuclear receptors offers a large number of targets to be pharmacologically exploited. Some nuclear receptors already look back to a successful history as drug targets, while others still lack any identified ligand. The development of small molecules targeting nuclear receptor is a challenging task and has to consider not only high affinity binding but also aspects as the nuclear localization of the target protein or transactivation efficacy. In this chapter, we summarize characteristics of nuclear receptors as target family, strategies of hit and lead identification, and the variety of methods for in vitro characterization of nuclear receptor modulators. A detailed method chapter describes an example optimization of a nuclear receptor modulator as well as hybrid reporter gene assays as a very flexible method of choice for in vitro characterization. Thereby, the chapter provides an introduction to nuclear receptor ligand development.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aranda A, Pascual A (2001) Nuclear hormone receptors and gene expression. Physiol Rev 81(3):1269–1304
Germain P, Chambon P, Eichele G et al (2006) International Union of Pharmacology. LX. Retinoic acid receptors. Pharmacol Rev 58(4):712–725
Evans RM, Mangelsdorf DJ (2014) Nuclear receptors, RXR, and the big bang. Cell 157(1):255–266. https://doi.org/10.1016/j.cell.2014.03.012
Germain P, Chambon P, Eichele G et al (2006) International Union of Pharmacology. LXIII. Retinoid X receptors. Pharmacol Rev 58(4):760–772. https://doi.org/10.1124/pr.58.4.7
de Lera AR, Bourguet W, Altucci L, Gronemeyer H (2007) Design of Selective Nuclear Receptor Modulators: RAR and RXR as a case study. Nat Rev Drug Discov 6(10):811–820. https://doi.org/10.1038/nrd2398
Nuclear Receptors Nomenclature Committee (1999) A unified nomenclature system for the nuclear receptor superfamily. Cell 97(2):161–163. https://doi.org/10.1016/S0092-8674(00)80726-6
Germain P, Staels B, Dacquet C et al (2006) Overview of nomenclature of nuclear receptors. Pharmacol Rev 58(4):685–704. https://doi.org/10.1124/pr.58.4.2
Merk D, Steinhilber D, Schubert-Zsilavecz M (2012) Medicinal chemistry of Farnesoid X receptor ligands: from agonists and antagonists to modulators. Future Med Chem 4(8):1015–1036. https://doi.org/10.4155/fmc.12.47
Proschak E, Heitel P, Kalinowsky L, Merk D (2017) Opportunities and challenges for fatty acid Mimetics in drug discovery. J Med Chem 60(13):5235–5266. https://doi.org/10.1021/acs.jmedchem.6b01287
Pellicciari R, Passeri D, De Franco F et al (2016) Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-Cholan-24-Oic acid (TC-100), a novel bile acid as potent and highly selective FXR agonist for Enterohepatic disorders. J Med Chem 59(19):9201–9214. https://doi.org/10.1021/acs.jmedchem.6b01126
Costantino G, Macchiarulo A, Entrena-Guadix A et al (2003) Binding mode of 6ECDCA, a potent bile acid agonist of the Farnesoid X receptor (FXR). Bioorg Med Chem Lett 13(11):1865–1868. https://doi.org/10.1016/S0960-894X(03)00281-6
Pellicciari R, Fiorucci S, Camaioni E et al (2002) 6α-ethyl-Chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with Anticholestatic activity. J Med Chem 45(17):3569–3572. https://doi.org/10.1021/jm025529g
Merk D, Steinhilber D, Schubert-Zsilavecz M (2014) Characterizing ligands for Farnesoid X receptor-available in vitro test Systems for Farnesoid X Receptor Modulator Development. Expert Opin Drug Discov 9(1):27–37. https://doi.org/10.1517/17460441.2014.860129
Flesch D, Cheung S-Y, Schmidt J et al (2017) Non-acidic Farnesoid X receptor modulators. J Med Chem 60(16):7199–7205. https://doi.org/10.1021/acs.jmedchem.7b00903
Achenbach J, Gabler M, Steri R et al (2013) Identification of novel Farnesoid X receptor modulators using a combined ligand- and structure-based virtual screening. MedChemComm 4(6):920. https://doi.org/10.1039/C3MD00049D
Merk D, Gabler M, Gomez RC et al (2014) Anthranilic acid derivatives as novel ligands for Farnesoid X receptor (FXR). Bioorg Med Chem 22(8):2447–2460. https://doi.org/10.1016/j.bmc.2014.02.053
Merk D, Lamers C, Ahmad K et al (2014) Extending the structure-activity relationship of anthranilic acid derivatives as Farnesoid X receptor modulators: development of a highly potent partial Farnesoid X receptor agonist. J Med Chem 57(19):8035–8055. https://doi.org/10.1021/jm500937v
Merk D, Lamers C, Weber J et al (2015) Anthranilic acid derivatives as nuclear receptor modulators—development of novel PPAR selective and dual PPAR/FXR ligands. Bioorg Med Chem 23(3):499–514. https://doi.org/10.1016/j.bmc.2014.12.013
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Schierle, S., Merk, D. (2018). Development of Nuclear Receptor Modulators. In: Mavromoustakos, T., Kellici, T. (eds) Rational Drug Design. Methods in Molecular Biology, vol 1824. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-8630-9_14
Download citation
DOI: https://doi.org/10.1007/978-1-4939-8630-9_14
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-8629-3
Online ISBN: 978-1-4939-8630-9
eBook Packages: Springer Protocols